**Question:** Confirmatory investigation for Acromegaly is:

A. Insulin-induced hypoglycemia test
B. Basal pituitary MRI
C. IGF-1 assay
D. Chromogranin A assay

**Correct Answer:** C. IGF-1 assay

**Core Concept:**
Acromegaly is a condition characterized by excessive growth hormone (GH) production due to a pituitary adenoma. Insulin-induced hypoglycemia test (A), basal pituitary MRI (B), and Chromogranin A assay (D) are not specific for GH excess and have limitations in diagnosing acromegaly.

**Why the Correct Answer is Right:**
The correct answer, IGF-1 assay (C), is a reliable diagnostic test for acromegaly as it measures the levels of insulin-like growth factor-1 (IGF-1) in the blood. IGF-1 is a downstream effector of GH and its levels are directly influenced by GH production. Elevated IGF-1 levels are consistent with acromegaly.

**Why Each Wrong Option is Incorrect:**

A. Insulin-induced hypoglycemia test (A) is used to diagnose somatotroph adenomas (which secrete GH) by assessing the response of GH secretion to hypoglycemia. However, it is not specific for GH excess and lacks sensitivity in the diagnosis of acromegaly.

B. Basal pituitary MRI (B) can demonstrate a pituitary mass, but it does not confirm the diagnosis of acromegaly. The MRI findings can be nonspecific and could be seen in other pituitary adenomas or even non-neoplastic conditions like pseudopseudohypoparathyroidism.

D. Chromogranin A assay (D) is an indirect marker of neuroendocrine tumors, including pituitary adenomas. However, it lacks sensitivity and specificity in diagnosing acromegaly as it can be elevated in many other conditions like neuroendocrine tumors, gastrinomas, and pheochromocytomas.

**Clinical Pearl:**
IGF-1 assay is a reliable confirmatory test in diagnosing acromegaly, especially when combined with clinical findings and other supportive investigations like MRI or GH stimulation tests.